Nonparticipants (n= 463) | Participants (n= 130) | P value | |
---|---|---|---|
Age (years) | 54.3 (46.0 to 64.1) | 52.3 (45.1 to 61.5) | 0.12 |
SSc duration by Raynaud's phenomenon (years) | 6.4 (3.4 to 11.7) | 7.0 (3.7 to 11.9) | 0.21 |
SSc duration by first non-Raynaud's symptom (years) | 5.4 (2.7 to 9.2) | 6.0 (3.0 to 10.3) | 0.20 |
Topoisomerase I (Scl70)-autoantibodiespositive | 42.8 | 46.7 | 0.44 |
Anti-centromere autoantibodies-positive | 14.9 | 15.7 | 0.82 |
U1RNP-positive | 6.5 | 4.7 | 0.51 |
RNA polymerase III-positive | 9.4 | 2.8 | 0.08 |
Diffuse SSc | 56.8 | 63.7 | 0.18 |
Puffy hands | 34.3 | 54.6 | < 0.001* |
mRSS | 10 (4 to 16) | 13 (6 to 20) | 0.01* |
mRSS > 20 | 16.8 | 25.0 | 0.05 |
C-reactive protein elevation | 33.6 | 24.5 | 0.07 |
Digital ulcers | 34.7 | 44.0 | 0.04* |
Synovitis | 13.1 | 20.0 | 0.05 |
Joint contractures | 33.0 | 31.8 | 0.81 |
Tendon friction rubs | 10.2 | 10.0 | 0.94 |
Muscle weakness | 22.2 | 20.9 | 0.76 |
Muscle atrophy | 11.1 | 15.5 | 0.17 |
Creatine kinase elevation | 11.6 | 13.3 | 0.58 |
Oesophageal symptoms | 54.4 | 60.4 | 0.23 |
Stomach symptoms | 16.0 | 13.5 | 0.50 |
Intestinal symptoms | 18.8 | 12.6 | 0.11 |
Lung fibrosis on chest X-ray or HRCT | 60.4 | 56.7 | 0.59 |
Forced vital capacity (% predicted) | 89 (75 to 101) | 92 (81 to 103) | 0.36 |
Forced vital capacity < 80% | 32.2 | 23.3 | 0.10 |
DLCO (% predicted) | 66 (49 to 82) | 69 (55 to 88) | 0.05 |
DLCO < 80% | 71. | 59.1 | 0.01* |
PAPsys (mmHg) | 30 (25 to 37) | 27 (20 to 36) | 0.004* |
PAPsys > 40 mmHg | 22.3 | 19.4 | 0.51 |
Diastolic dysfunction | 20.4 | 18.8 | 0.70 |
Pericardial effusion | 7.1 | 5.7 | 0.64 |
Left ventricular ejection fraction < 60% | 25.1 | 20.0 | 0.31 |
Arterial hypertension | 21.5 | 23.6 | 0.75 |
Renal crisis | 3.3 | 4.5 | 0.50 |
Proteinuria | 8.6 | 9.4 | 0.79 |
EULAR SSc activity score | 1.5 (0.5 to 3.0) | 2 (0.5 to 3.5) | 0.27 |
High SSc activity (score ≥ 3) | 27.2 | 35.2 | 0.19 |
Hypocomplementaemia | 5.0 | 5.9 | 0.71 |